Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Advanced Synovial Sarcoma
NCT00052754Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2002
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in synovial sarcoma (SS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free rate at 12 weeks. Started Oct 2002; status: completed.
02
Drugs
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT00052754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052754.